Cardipro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardipro

Property Description
Active ingredient Atenolol
Form Oral tablet
Pharmacological class beta-Adrenergic Blocking Agent (beta-Blocker)
Common use Cardiovascular stabilization (General Purpose)
Origin Synthetic compound

Cardipro is a prescription-only pharmaceutical containing the single active ingredient Atenolol. This substance is formally classified by the World Health Organization as a beta-Adrenergic Receptor Antagonist, commonly known as a beta-blocker. The classification establishes Atenolol's role as a medicine clinically recognized for regulating activity within the circulatory system.

Atenolol is a synthetic compound that functions specifically as a cardioselective beta1-antagonist. This means its chemical structure is designed to primarily block the effects of stimulating hormones, like adrenaline, at the beta1 receptors found mainly within the heart muscle, providing a focused cardioprotective effect. Pharmacological studies confirm the efficacy of this selective mechanism, which targets cardiac function more specifically than non-selective alternatives.

Composition and General Purpose of Atenolol Monotherapy

Cardipro is manufactured as an oral tablet formulation, which is considered a single-ingredient product (monotherapy), containing only Atenolol alongside pharmaceutical excipients. This dosage form is designed for oral route of administration and systemic absorption throughout the body, suitable for the typical adult patient requiring chronic cardiovascular management.

The fundamental general purpose of this medicine stems from its core action on the heart: to help reduce strain and oxygen demand on the cardiac muscle. Atenolol accomplishes this by inhibiting sympathetic stimulation, resulting in a negative chronotropic effect (slowing the heart rate) and a negative inotropic effect (reducing the force of heart muscle contraction). By consistently stabilizing the heart's activity, the medicine contributes to the maintenance of overall cardiovascular equilibrium, providing a baseline regulatory effect for heart function.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Cardipro?

Possible Side Effects and Safety Information

The safety profile of Cardipro, as documented in regulatory health authority reports, includes information on serious risks and common adverse reactions categorized by body system.

Serious Systemic Risks

Official prescribing information includes warnings about serious, potentially life-threatening risks, which may occur early in treatment and can increase with the duration of use:

  • Serious Cardiovascular Thrombotic Events: The medicine may increase the risk of serious cardiovascular events, including myocardial infarction (heart attack) and stroke.
  • Serious Gastrointestinal Adverse Events: Risks include bleeding, ulceration, and perforation of the stomach or intestines, which may be fatal.

Safety Restrictions and Contraindications

The medicine is restricted for use in certain situations due to the high risk of harm:

  • It must not be used for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • It is contraindicated in patients with a known hypersensitivity to the drug or in those with active gastrointestinal bleeding or ulceration.

Documented Adverse Reactions

Adverse reactions are organized by the affected System-Organ Class and severity. The most common documented reactions often involve the gastrointestinal system, including symptoms such as dyspepsia (indigestion), nausea, and abdominal pain. Other reported reactions affect the renal system (renal injury), hepatic system (elevated liver enzymes), and the blood and lymphatic system (anemia).

Serious reactions involving the skin, such as exfoliative dermatitis and Stevens-Johnson syndrome, have been documented but are considered rare. Healthcare providers are advised to use the lowest effective dose for the shortest duration necessary to minimize these risks.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Cardipro (Atenolol) is formally documented to present with exaggerated extensions of its core pharmacological effects. Manifestations may include Symptomatic Bradycardia (an abnormally slow heart rate), Hypotension (severely low blood pressure), and Hypoglycemia (low blood sugar). In certain cases, Bronchospasm and profound Lethargy may also occur.


Severe Manifestations and Required Actions

The most critical documented outcome of Cardipro overdose is the potential for Acute Cardiac Failure, which may lead to Cardiogenic Shock. Due to the life-threatening nature of these cardiac events, regulatory authorities mandate that suspected overdose cases require immediate medical attention and management in a hospital setting.

Treatment for overdose is strictly symptomatic and supportive, as no specific antidote is known to exist for Atenolol. Measures described in official guidance include procedures such as Gastric Lavage or the administration of Activated Charcoal to reduce absorption of the unabsorbed drug. Intensive monitoring of vital signs, including heart rate and blood pressure, is necessary for patient stabilization.

A specific consideration noted in official documentation is the increased potential for severe and prolonged overdose effects in patients with impaired renal function, as the body relies on the kidneys to eliminate the substance. This accumulation necessitates caution and adjusted monitoring in this specific population.

Therapeutic Uses of Cardipro

What Cardipro Treats: Main Uses and Benefits

Cardipro (Atenolol) is generally used for its ability to stabilize cardiovascular activity, targeting core symptoms related to heightened physiological activity. The therapeutic scope is commonly centered on providing supportive relief and management across several key therapeutic domains.

This medication is applied to manage symptoms in conditions like chronic high blood pressure (hypertension), is commonly used to help with managing symptoms related to chest pain (Angina Pectoris), and to assist with certain irregular heart rhythms (arrhythmias). It is also relevant for the preventative management of specific episodic manifestations, such as debilitating migraines.

By easing these heightened manifestations, Cardipro provides symptomatic relief that helps patients cope more steadily with disruptive episodes. It supports the patient during difficult episodes by easing distress and contributes to maintaining functional stability when symptoms are more noticeable.

“It supports the patient during difficult episodes by easing distress and contributes to maintaining functional stability.”

Quick Fact: Relief for Cardiovascular Over-stimulation Cardipro is used for managing symptoms of cardiac over-stimulation like palpitations, offering supportive relief to support the patient during episodes of heightened discomfort.

Regulatory References

  1. U.S. National Library of Medicine (NIH) and FDA

Eligibility and Restrictions for Use

Eligibility and Contraindications for Cardipro (Atenolol)

The official regulatory labeling for Cardipro strictly defines the patient populations permitted to use the medicine and those who must not. Use is generally established for adult patients under standard labeled conditions.

Absolute Contraindications

Cardipro is contraindicated and must not be used by patients presenting with the following conditions, as stated in the prescribing information:

  • Second or third-degree heart block (Heart block greater than first degree).
  • Cardiogenic shock or overt cardiac failure (decompensated heart failure).
  • Sinus bradycardia (very slow heart rate, typically below 50 beats per minute).
  • Hypersensitivity (allergy) to atenolol or any components of the formulation.

Population Restrictions and Cautions

Population Category Regulatory Status
Pediatric Population Safety and efficacy have not been established; use is not recommended in children.
Severe Renal Impairment Use is restricted; significant accumulation occurs when kidney function is severely limited.
Pregnancy Use is restricted due to documented risks of fetal growth restriction.
Lactation (Breastfeeding) Use is cautioned; the medicine is excreted into human milk, posing a risk of bradycardia in the infant.
Asthma/Severe COPD Use is strongly restricted due to the potential for adverse pulmonary effects.
Older Adults Use is permitted but requires caution due to a greater likelihood of reduced renal clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the official interaction patterns for Cardipro (Atenolol) as documented in government regulatory sources. These interactions are categorized based on their mechanism and official restrictions.


Documented Interaction Patterns

Interaction Type Interacting Medicines Official Statement / Constraint
Pharmacodynamic Enhancement Digitalis (Digoxin), Verapamil, Diltiazem, Amiodarone Documented risk of additive cardiotoxicity, including pronounced slowing of the heart rate (bradycardia) or AV block.
Pharmacodynamic Antagonism Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), e.g., Aspirin Long-term use of certain NSAIDs may officially reduce the blood pressure-lowering effect of Atenolol.
Reduced Absorption Aluminum Hydroxide (Antacid) Decreases the absorption and plasma concentration of Atenolol. Regulatory documents require co-administration to be separated by at least two hours.

Population and Clearance Notes

Cardipro is primarily eliminated by the kidneys. Therefore, caution is officially noted for patients with impaired renal function, as reduced clearance may heighten the risk of drug accumulation and associated interactions.

Contraindications and Metabolism

Official regulatory documentation does not list any medicines as strictly prohibited (contraindicated due to interaction risk) within the Drug Interactions section. Atenolol is also noted to undergo minimal liver metabolism, resulting in no documented interactions involving the CYP450 enzyme system.

Mechanism of Action

Cardipro (Atenolol) functions as a selective mathbfbeta1-adrenergic receptor antagonist, engaging mechanisms that influence sympathetic signaling pathways. Its mechanism of action is primarily peripheral and involves two principal mechanistic domains that contribute to its physiological effects: cardiac receptor blockade and systemic pathway modulation.

Cardioselective Receptor Blockade

Cardipro's primary mechanism is the competitive blockade of mathbfbeta1-receptors located predominantly in the heart. This action suppresses the stimulatory effects of circulating Adrenaline and Norepinephrine on the myocardium. The resulting mechanistic cascade—a decrease in intracellular cAMP and calcium influx—modifies early molecular steps that influence subsequent systemic physiological events. This mechanism directly produces a reduction in the heart's spontaneous firing rate (mathbfnegative chronotropy) and a decrease in its contractile force (mathbfnegative inotropy).

Renal System Pathway Modulation

Due to its low lipophilicity, the drug's mechanism is concentrated peripherally, but also influences feedback regulation within the Renin-Angiotensin-Aldosterone System (RAAS). By blocking the beta1 receptors on the juxtaglomerular cells in the kidney, Cardipro suppresses the release of Renin. This modulation of a systemic regulatory pathway reduces the influence of excessive mediator activity and influences systemic vascular tone and fluid balance.

Dosage and Administration Information

Official Administration Guidelines

Cardipro (Atenolol) is primarily administered as an oral tablet for chronic management, taken typically once daily. An intravenous (IV) injection formulation is also an approved route of administration used for acute intervention in monitored hospital settings, such as initial management following a myocardial infarction.

The standard oral dose for managing hypertension or angina usually ranges from 50 mg to 100 mg per day. The tablets may be taken with or without food and should be swallowed whole with liquid. If dose adjustment is necessary, the official schedule recommends waiting one to two weeks to fully observe the therapeutic effect before making changes.

Official prescribing information mandates special dose adjustment protocols for certain populations. Patients with impaired kidney function require a significantly reduced daily dose, determined by their creatinine clearance. For older adults, the label suggests initiating therapy at the low end of the dosing range, such as 25 mg once daily. Critically, the long-term use pattern requires that treatment must not be stopped abruptly; instead, discontinuation must be gradually tapered over a period of one to two weeks, as outlined in established protocols. If a daily dose is missed, it should be skipped if it is almost time for the next dose; a double dose must never be taken.

Recent Clinical Evidence

Cardipro: Overview of Clinical Studies

Evidence for Use in Chronic High Blood Pressure (Hypertension)

Research for chronic high blood pressure was evaluated in large-scale Randomized Controlled Trials (RCTs) and Systematic Reviews and Meta-Analyses. These studies monitored key physiological outcomes such as changes in both resting and exercise Systolic and Diastolic Blood Pressure (BP). Findings described patterns related to changes in blood pressure measurements. However, when compared to other drug classes in long-term reports, the findings were mixed regarding the prevention of major cardiovascular events. Some data show patterns that are associated with a higher incidence of stroke compared to patients receiving certain newer types of blood pressure medication. High-quality comparative data for Cardipro as an initial, stand-alone treatment for hypertension is limited.


Evidence for Use in Managing Chest Pain (Angina Pectoris)

Research exploring Cardipro for stable chest pain was studied for in Controlled Trials. Researchers examined outcomes related to physical discomfort, such as changes in the frequency of Angina Attacks, and monitored associated medication consumption. Studies also explored outcomes reflecting daily functioning by measuring Exercise Tolerance and monitoring changes in Heart Rate. Findings described changes in the frequency of anginal episodes and patterns related to physical exertion capacity during standardized tests. The evidence highlights a consistent pattern of potential symptom exacerbation observed in studies where the medication was discontinued suddenly.


Evidence in Specific Patient Populations

Research has explored the use of Cardipro in several patient groups that require specific consideration. For instance, research explored outcomes in elderly patients and specifically examined outcomes in patients with impaired kidney function. Sub-group analyses were also conducted to examine outcomes in patients from different ethnic groups, with some findings indicating that responsiveness may vary across these groups. Data for certain groups, such as those with high-risk comorbidities, remain insufficient for establishing broad findings.

Key Studies & References

  1. Label: ATENOLOL tablet - DailyMed (Used for all three primary indications: Hypertension, Angina Pectoris, and Acute Myocardial Infarction, plus basic information on renal clearance and elderly patients)
  2. Should beta blockers remain first choice in the treatment of primary hypertension: a meta-analysis (Review of stroke risk compared to other classes and placebo)
  3. Atenolol: Side Effects, Uses, Dosage, Interactions, Warnings (Used for general context, specific study exclusions like low BP/HR in post-MI, and abrupt withdrawal risk)

Frequently Asked Questions (FAQ)

Common questions about Cardipro (FAQ)

Q: Is Cardipro considered a high-risk medication?

A: Official warnings state that Cardipro carries specific Serious Systemic Risks, such as the potential for cardiovascular thrombotic events and serious gastrointestinal issues. Regulatory guidance emphasizes that the lowest effective dose is used for the shortest necessary duration. This information is intended to help guide the management of potential risks.


Q: What is the difference between Cardipro and its main competitor, [generic name]?

A: Cardipro is the brand name for the generic medicine Atenolol, which is classified as a beta1-adrenergic receptor antagonist, commonly called a cardioselective beta-blocker. This classification indicates that the medicine's main mechanism is blocking beta1-receptors predominantly located in the heart. This action suppresses the stimulatory effects of natural chemicals like adrenaline.


Q: Are there any long-term side effects that regulatory agencies mention?

A: Official drug warnings state that certain serious systemic risks, including cardiovascular thrombotic events and gastrointestinal adverse events, may increase with the duration of use. This is a factor considered when determining the duration of treatment.


Q: Are there specific foods or dietary supplements I should avoid while on Cardipro?

A: Official prescribing information states that Cardipro tablets may be taken with or without food. However, some data suggests that consuming large amounts of orange juice at the same time may decrease how well the drug works. Taking the medicine at a consistent time each day is often advised.


Q: What is the main purpose of the different strengths (milligrams) of Cardipro?

A: Cardipro is available in different strengths to allow a doctor to properly adjust the dose based on the patient's specific therapeutic needs. Regulatory guidelines note that lower initial doses may be necessary for individuals with impaired kidney function or for older adults starting therapy.


Q: Do the side effects from Cardipro go away after the first few weeks of taking it?

A: According to patient information linked to regulatory sources, common initial side effects such as dizziness, feeling sick (nausea), or tiredness are usually mild and are not typically long-lasting. This temporary pattern may be part of the body adjusting to the medication.


Q: Has Cardipro been associated with weight gain or changes in appetite?

A: Official documents mention unusual weight gain as a reported side effect associated with the medicine. Furthermore, any sudden or unexplained weight gain may also be a sign of a worsening underlying heart condition, and is a factor that is noted.


Q: Can taking Cardipro cause dizziness or lightheadedness?

A: Yes, official safety information lists both dizziness and lightheadedness as reported side effects. These effects may be more noticeable when first starting the medication or if the dosage is adjusted.


Q: Is it normal to feel a little tired or fatigued when first starting Cardipro?

A: Regulatory safety information lists tiredness and a lack of energy as documented side effects. If these feelings are persistent or severe, it is a point noted for discussion with a healthcare provider.


Q: Does Cardipro affect sleep patterns or cause insomnia?

A: Official documents include reports of central nervous system (CNS) effects such as drowsiness and dreaming. Some patient information notes that issues with sleeping or experiencing unusual dreams have been reported by users.


Q: What should a patient expect Cardipro to feel like when it is working properly?

A: When taking Cardipro for high blood pressure, a patient may not feel any different, as the medicine works internally to lower blood pressure and slow the heart rate. Continued use of the medication as directed is indicated, as the intended effect is often not felt subjectively.


Q: How quickly does Cardipro start to work after the first dose?

A: According to regulatory pharmacokinetics data, the initial beta-blocking effects are apparent within 1 hour after taking a single oral dose. The maximal effect is typically achieved within 2 to 4 hours following administration.


Q: How long does Cardipro typically stay in the body after a dose?

A: Regulatory documents state that the elimination half-life of Cardipro is typically 6 to 7 hours in individuals with normal kidney function. Despite this, the blood pressure-lowering effects are designed to last for at least 24 hours.


Q: Is it safe to take cold and flu remedies with Cardipro?

A: Official interaction warnings advise caution with taking over-the-counter (OTC) cold and flu remedies that may contain ingredients that raise blood pressure. Patients are generally directed to consult with a healthcare provider before taking any OTC products to check for interactions.


Q: What is the guidance on consuming alcohol while taking Cardipro?

A: Regulatory information indicates that Atenolol and alcohol (ethanol) may have additive effects in lowering blood pressure. This combined effect can potentially increase the risk of side effects such as dizziness, lightheadedness, or fainting.


Q: Can Cardipro interact with herbal or natural remedies?

A: Official interaction warnings state that the process of informing their healthcare provider about all medicines used is important, including vitamins and any herbal or natural remedies. This ensures that the provider can check for potential drug interactions.


Q: What is the official guidance for taking Cardipro during pregnancy or breastfeeding?

A: The drug label states that use during pregnancy should only occur if the benefit to the mother outweighs the potential risk, and newborn monitoring is indicated for signs of beta-blockade. Since the drug is excreted into human milk, breastfed infants, especially newborns, are also monitored for signs such as an unusually slow heart rate (bradycardia) or low blood sugar (hypoglycemia).


Q: Can Cardipro be prescribed to children or teenagers?

A: Official use information indicates that Atenolol has approved use for the treatment of high blood pressure in pediatric patients. The determination of dosage, administration, and monitoring in this population is performed by a healthcare provider.


Q: Is there a generic version of Cardipro available yet?

A: Cardipro is the brand name for the active drug substance, which has the official generic name Atenolol. The medication is widely available generically and is often referred to by its generic name.


Q: Does Cardipro treat the cause of the heart issue or just manage the symptoms?

A: The medication's mechanism involves blocking the action of natural chemicals like adrenaline and norepinephrine to manage physiological activity, such as lowering heart rate and blood pressure. This action is considered a management of symptoms and cardiovascular function, rather than a cure for the underlying heart condition.


Q: Are there ongoing research studies looking into new uses for Cardipro?

A: Information on ongoing or past research studies involving Cardipro (Atenolol) for various conditions can be found on regulatory databases, such as the NIH ClinicalTrials.gov website, which provides public access to study details.


Q: Why is Cardipro sometimes referred to by a chemical name instead of the brand name?

A: Cardipro is the brand name for the active drug substance, which has the official generic name Atenolol. Regulatory documents and healthcare providers often use the generic name, Atenolol, to refer to the active drug substance itself, regardless of who manufactures it.


Q: Does Cardipro affect or interact with birth control pills?

A: Official interaction warnings state that Atenolol undergoes minimal liver metabolism by the enzyme system most commonly associated with reducing contraceptive effectiveness. For this reason, it is not generally expected to interfere with the effectiveness of hormonal birth control pills.


Q: Is it necessary to have blood work done regularly while taking Cardipro?

A: Official patient information notes that blood pressure and heart rate are checked regularly while taking the medication. Furthermore, monitoring for low blood sugar (hypoglycemia) is officially noted in certain patient populations, such as those with diabetes or children.


Q: Can Cardipro affect one's ability to drive or operate machinery?

A: Official warnings advise patients to use caution with activities that require alertness, such as driving a car or operating machinery. This is due to the potential risk of side effects like dizziness, lightheadedness, or tiredness, which are noted in the safety information.

How should Cardipro be stored and disposed of?

Storage Requirements

Cardipro must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted brief temperature excursions up to 30 C (86 F). The product must be kept in its original container, which should remain tightly closed to protect it from moisture and excess heat. Official labeling requires storing the medication in a dry place and avoiding humid environments such as a bathroom.

Child Safety and Disposal

For child safety, Cardipro must be stored out of the sight and reach of children in a secure location. When disposing of unused or expired tablets, the official guidance is to use a drug take-back program. It is strictly prohibited to flush the medicine down a toilet or pour it down a drain unless the product's labeling specifically directs this method of disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardipro found in:

A-Z Index: